Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amneal Pharmaceuticals Inc (AMRX)
NASDAQ:AMRX
Holding AMRX?
Track your performance easily
AMRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.01 - $9.48
Previous Close$7.78
Volume1.66M
Average Volume (3M)1.07M
Market Cap
$2.40B
Enterprise Value$4.92B
Total Cash (Recent Filing)$74.01M
Total Debt (Recent Filing)$2.53B
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Feb 27, 2025EPS Estimate
$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding309,844,430
10 Day Avg. Volume910,264
30 Day Avg. Volume1,073,292
Standard Deviation0.16
R-Squared0.13
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-25.93
Price to Sales (P/S)0.90
Price to Cash Flow (P/CF)4.20
P/FCF Ratio5.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.84
Enterprise Value/Gross Profit6.00
Enterprise Value/Ebitda21.09
Forecast
1Y Price Target
$10.50Price Target Upside34.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Amneal Pharmaceuticals News
PremiumCompany Announcements
Amneal Pharmaceuticals Reports Q3 2024 Financial Results
Ownership Overview
25.76% Insiders
8.97% Mutual Funds
12.89% Other Institutional Investors
43.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMRX FAQ
What was Amneal Pharmaceuticals Inc’s price range in the past 12 months?
Amneal Pharmaceuticals Inc lowest stock price was $5.01 and its highest was $9.47 in the past 12 months.
What is Amneal Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Amneal Pharmaceuticals Inc’s upcoming earnings report date?
Amneal Pharmaceuticals Inc’s upcoming earnings report date is Feb 27, 2025 which is in 67 days.
How were Amneal Pharmaceuticals Inc’s earnings last quarter?
Amneal Pharmaceuticals Inc released its earnings results on Nov 08, 2024. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.134 by $0.026.
Is Amneal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amneal Pharmaceuticals Inc’s price is currently Undervalued.
Does Amneal Pharmaceuticals Inc pay dividends?
Amneal Pharmaceuticals Inc does not currently pay dividends.
What is Amneal Pharmaceuticals Inc’s EPS estimate?
Amneal Pharmaceuticals Inc’s EPS estimate is $0.15.
How many shares outstanding does Amneal Pharmaceuticals Inc have?
Amneal Pharmaceuticals Inc has 309,844,420 shares outstanding.
What happened to Amneal Pharmaceuticals Inc’s price movement after its last earnings report?
Amneal Pharmaceuticals Inc reported an EPS of $0.16 in its last earnings report, beating expectations of $0.134. Following the earnings report the stock price went up 1.394%.
Which hedge fund is a major shareholder of Amneal Pharmaceuticals Inc?
Among the largest hedge funds holding Amneal Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Amneal Pharmaceuticals Inc’s shares valued at 13M.
---
Amneal Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (34.96% Upside)
$10.50 (34.96% Upside)
Blogger Sentiment
Bullish
AMRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 442.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $967.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.06%
12-Months-Change
Fundamentals
Return on Equity
-155.38%
Trailing 12-Months
Asset Growth
-6.13%
Trailing 12-Months
Company Description
Amneal Pharmaceuticals Inc
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.
---
AMRX Company Deck
---
AMRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth and strategic initiatives such as the Metsera collaboration and the launch of CREXONT, contributing to a positive outlook. However, challenges such as the upcoming loss of exclusivity for Rytary and increased interest expenses were noted, though they are being mitigated by other growth drivers.Read More>---
AMRX Stock 12 Month Forecast
Average Price Target
$10.50
▲(34.96% Upside)
Technical Analysis
Best Analysts Covering AMRX
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+53.24%
reiterated a buy rating last month
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +53.24% per trade.
---